Profile data is unavailable for this security.
About the company
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing transformative therapies for rare and neurological diseases with limited treatment options. The Company’s Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin. It is an orphan drug designated product in the United States and Europe, and is the subject of four formal clinical trials for Niemann-Pick Disease Type C (NPC) disease. NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. The Company is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842).
- Revenue in USD (TTM)1.13m
- Net income in USD-20.74m
- Incorporated2020
- Employees8.00
- LocationCyclo Therapeutics Inc6714 Nw 16Th Street, Suite BGAINESVILLE 32653United StatesUSA
- Phone+1 (386) 418-8060
- Websitehttps://www.cyclotherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunoprecise Antibodies Ltd | 17.28m | -19.80m | 13.55m | 102.00 | -- | 0.5446 | -- | 0.7843 | -0.7482 | -0.7482 | 0.6606 | 0.863 | 0.3546 | 6.12 | 6.16 | -- | -40.63 | -26.70 | -46.68 | -30.31 | 48.21 | 56.13 | -114.58 | -85.72 | 0.8189 | -134.72 | 0.3289 | -- | 18.65 | 17.54 | -2.32 | -- | 16.71 | -- |
| Onconetix Inc | 1.46m | -53.12m | 14.60m | 12.00 | -- | -- | -- | 9.97 | -104.90 | -104.90 | 2.89 | 50.92 | 0.0328 | 3.45 | 5.30 | 121,979.20 | -119.09 | -- | -215.11 | -- | -57.21 | -- | -3,629.24 | -- | 0.091 | -11.87 | 0.2984 | -- | -- | -- | -176.78 | -- | -- | -- |
| Bright Green Corp | 0.00 | -9.92m | 15.33m | 5.00 | -- | 1.54 | -- | -- | -0.0538 | -0.0538 | 0.00 | 0.0519 | 0.00 | -- | -- | 0.00 | -47.48 | -- | -72.55 | -- | -- | -- | -- | -- | -- | -- | 0.0494 | -- | -- | -- | 52.54 | -- | -- | -- |
| Talphera Inc | 398.00k | -13.70m | 15.46m | 15.00 | -- | 1.21 | -- | 38.85 | -0.6353 | -0.6323 | 0.0185 | 0.7491 | 0.0187 | -- | -- | 26,533.33 | -64.37 | -22.60 | -78.11 | -28.55 | -- | -- | -3,443.22 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
| Cumberland Pharmaceuticals, Inc. | 37.79m | -10.38m | 16.81m | 91.00 | -- | 0.6414 | -- | 0.445 | -0.7328 | -0.7328 | 2.67 | 1.87 | 0.4501 | 0.8643 | 3.17 | 415,225.80 | -12.35 | -7.03 | -17.75 | -9.52 | 82.58 | 79.95 | -27.45 | -17.64 | 1.26 | -38.85 | 0.382 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| TherapeuticsMD Inc | 996.00k | -4.83m | 17.30m | 1.00 | -- | 0.6252 | -- | 17.37 | -0.4348 | -0.5538 | 0.0889 | 2.40 | 0.0212 | -- | 0.5048 | 996,000.00 | -10.31 | -53.35 | -13.13 | -111.61 | 45.08 | 86.67 | -485.34 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
| Cara Therapeutics Inc | 11.00m | -111.08m | 18.70m | 55.00 | -- | 1.61 | -- | 1.70 | -2.04 | -2.04 | 0.2017 | 0.2115 | 0.1063 | 1.10 | 2.10 | 199,927.30 | -107.38 | -35.76 | -132.61 | -40.82 | 74.66 | -- | -1,010.20 | -162.10 | 4.48 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Marinus Pharmaceuticals Inc | 30.26m | -149.24m | 19.00m | 165.00 | -- | -- | -- | 0.6278 | -2.66 | -2.66 | 0.5391 | -0.8614 | 0.21 | 0.7508 | 6.98 | 183,412.10 | -103.54 | -49.64 | -131.60 | -57.76 | 90.64 | -- | -493.14 | -518.96 | 2.15 | -11.80 | 6.10 | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
| Cyclo Therapeutics Inc | 1.13m | -20.74m | 21.24m | 8.00 | -- | -- | -- | 18.75 | -0.9104 | -0.9104 | 0.0474 | -0.1785 | 0.242 | 0.4002 | 13.16 | 141,553.80 | -443.08 | -132.22 | -- | -215.17 | 91.56 | 90.37 | -1,831.29 | -1,114.04 | 0.4283 | -- | -- | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
| Gelteq Ltd | 0.00 | -1.55m | 21.24m | -- | -- | 1.49 | -- | -- | -0.1617 | -0.1617 | 0.00 | 1.51 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.38 | -32.41 | 0.0605 | -- | -- | -- | -72.77 | -- | -- | -- |
| China Health Industries Holdings, Inc. | 95.95k | -1.36m | 21.30m | 32.00 | -- | -- | -- | 221.99 | -0.0208 | -0.0208 | 0.0015 | -0.0366 | 0.0037 | 0.5035 | 20.57 | 2,998.44 | -5.18 | 3.04 | -6.89 | 3.66 | -5.34 | 69.55 | -1,419.49 | 28.61 | 0.0377 | -- | 1.76 | -- | 41,225.93 | -55.72 | -15.49 | -- | -- | -- |
| Nexgel Inc | 5.01m | -3.39m | 21.32m | 19.00 | -- | 4.78 | -- | 4.26 | -0.5722 | -0.5722 | 0.8464 | 0.6589 | 0.4942 | 3.03 | 6.44 | 263,631.60 | -35.74 | -44.61 | -48.15 | -56.19 | 23.74 | 5.02 | -72.33 | -180.98 | 0.8135 | -- | 0.1992 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| Polypid Ltd | 0.00 | -24.70m | 23.81m | 59.00 | -- | 10.49 | -- | -- | -9.65 | -9.65 | 0.00 | 0.3337 | 0.00 | -- | -- | 0.00 | -107.89 | -76.92 | -164.39 | -89.61 | -- | -- | -- | -- | -- | -24.21 | 0.8425 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
| Tonix Pharmaceuticals Holding Corp | 12.46m | -149.01m | 25.89m | 103.00 | -- | 0.0339 | -- | 2.08 | -110.99 | -110.99 | 6.16 | 4.28 | 0.1083 | 0.8436 | -- | 120,951.50 | -129.55 | -59.46 | -157.22 | -65.92 | 21.59 | -- | -1,196.12 | -5,126.73 | 0.7181 | -- | 0.1678 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
| Natural Alternatives International, Inc. | 113.80m | -7.22m | 26.72m | 296.00 | -- | 0.3235 | -- | 0.2348 | -1.23 | -1.23 | 19.38 | 13.32 | 0.7676 | 3.96 | 9.52 | 384,445.90 | -4.87 | 2.33 | -5.61 | 2.80 | 6.03 | 14.24 | -6.34 | 2.06 | 1.59 | -10.21 | 0.1326 | 0.00 | -26.11 | -3.82 | -386.16 | -- | -10.75 | -- |
| BioXcel Therapeutics Inc | 2.40m | -107.83m | 27.09m | 74.00 | -- | -- | -- | 11.28 | -3.56 | -3.56 | 0.074 | -1.84 | 0.0234 | 0.5941 | 3.87 | 32,472.97 | -104.93 | -74.57 | -150.29 | -84.06 | 43.07 | -- | -4,487.39 | -32,300.74 | 2.25 | -10.10 | 3.59 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
Data as of Nov 13 2024. Currency figures normalised to Cyclo Therapeutics Inc's reporting currency: US Dollar USD
5.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| EPIQ Capital Group LLCas of 30 Jun 2024 | 817.27k | 2.85% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 446.57k | 1.56% |
| Geode Capital Management LLCas of 30 Jun 2024 | 175.42k | 0.61% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 56.85k | 0.20% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 39.53k | 0.14% |
| Citadel Securities LLCas of 30 Jun 2024 | 24.67k | 0.09% |
| Wealth Enhancement Advisory Services LLCas of 30 Sep 2024 | 23.40k | 0.08% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 21.72k | 0.08% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 13.36k | 0.05% |
| UBS Securities LLCas of 30 Jun 2024 | 7.53k | 0.03% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
